Page last updated: 2024-09-04

atrasentan and Kidney Failure

atrasentan has been researched along with Kidney Failure in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Tobe, S; Waijer, SW	1
de Zeeuw, D; Heerspink, HJL; Koomen, JV; Mostafa, NM; Parving, HH; Stevens, J	1
Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M; Yi, T	1
Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F	1

Trials

3 trial(s) available for atrasentan and Kidney Failure

Article	Year
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Clinical journal of the American Society of Nephrology : CJASN, 2021, Volume: 16, Issue:12 Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic	2021
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Biological Variation, Population; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Metabolic Clearance Rate; Renal Elimination; Renal Insufficiency; Severity of Illness Index; Sodium	2018
Baseline characteristics and enrichment results from the SONAR trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diuretics; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Precision Medicine; Renal Insufficiency; Risk	2018

Other Studies

1 other study(ies) available for atrasentan and Kidney Failure

Article	Year
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat. European journal of pharmacology, 2009, Apr-01, Volume: 607, Issue:1-3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency	2009

Article

Year

Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.

European journal of pharmacology, 2009, Apr-01, Volume: 607, Issue:1-3

Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency

2009